Abbott Laboratories (ETR:ABL)
Germany · Delayed Price · Currency is EUR | Market Cap | 193.30B |
| Revenue (ttm) | 37.37B |
| Net Income (ttm) | 11.87B |
| Shares Out | n/a |
| EPS (ttm) | 6.78 |
| PE Ratio | 16.29 |
| Forward PE | 23.06 |
| Dividend | 2.11 (1.89%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 444 |
| Average Volume | 635 |
| Open | 111.34 |
| Previous Close | 112.20 |
| Day's Range | 110.90 - 111.70 |
| 52-Week Range | 104.08 - 134.14 |
| Beta | 0.72 |
| RSI | 52.22 |
| Earnings Date | Jan 22, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
Abbott issues US device correction for some glucose monitors over faulty readings risk
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some...
See Which Of The Latest 13F Filers Holds ABT
At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2025 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these...
Alphabet, Exact Sciences, And Regeneron Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 17-Nov. 21): Are the Others in Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio ? Exact Sciences Corporation (NASDAQ: EXAS) gained 48.97% this week after Abbott Laboratories (NYSE: ABT)a...
ABT Quantitative Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of ...
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact...
Abbott Laboratories: Not Passing The Test, After Buying Test Maker Exact Sciences
Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Read what this means for investors and when value could improve.
Top 2 Healthcare Stocks Every New Investor Should Know
These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.
2 Fantastic Dividend Stocks to Buy and Hold Forever
Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1372891929-1fc39a3b97984d12bebebf9567b6a270.jpg)
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion.
Exact Sciences Corporation (EXAS) Abbott Laboratories, - M&A Call - Slideshow
2025-11-20. The following slide deck was published by Exact Sciences Corporation in conjunction with this event.
Abbott Labs Expands into Cancer Diagnostics with Exact Sciences Acquisition
Abbott Labs Expands into Cancer Diagnostics with Exact Sciences Acquisition
Abbott Laboratories (ABT) Announces Merger Agreement with Exact Sciences
Abbott Laboratories (ABT) Announces Merger Agreement with Exact Sciences
Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics
Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately ...
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott To Acquire Exact Sciences For About $23 Billion
(RTTNews) - Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement,...
Abbott to Acquire Exact Sciences for $21 Billion
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business.
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics...
BTIG Reiterates Buy Rating for Abbott Laboratories (ABT) with Price Target Maintained | ABT ...
BTIG Reiterates Buy Rating for Abbott Laboratories (ABT) with Price Target Maintained | ABT Stock News
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories
Exact Sciences stock catapulted Wednesday amid rumors Abbott Laboratories is nearing a deal to buy the cancer-finding specialist.
Abbott Laboratories (ABT) Approaches Possible Acquisition of Exact Sciences
Abbott Laboratories (ABT) Approaches Possible Acquisition of Exact Sciences
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.